Lung Cancer Clinical Trials

Showing 2841-2860 of 4,288 trials

Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients

NCT00137800

The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70 years of age or older.

Non-Small-Cell Lung Carcinoma

Dana-Farber Cancer Institute82 participantsStarted Feb 2003

Boston, Massachusetts, United States • Boston, Massachusetts, United States

UNKNOWNPhase 4

Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

NCT03755869

Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor celltebiz related kinase -c-Kit kinase. In the phase III study, Patients who failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib (12mg, po. qd. on day 1to14 of a 21-day cycle) or placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months.

Non-squamous NSCLC

First Affiliated Hospital Xi'an Jiaotong University103 participantsStarted Nov 2018

Xian, Shanxi, China

COMPLETEDPhase 3

Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer

NCT00003011

RATIONALE: Marimastat may stop the growth of lung cancer by stopping blood flow to the tumor. It is not yet known if marimastat is an effective treatment for small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of marimastat with a placebo following chemotherapy in treating patients who have small cell lung cancer.

Lung Cancer

NCIC Clinical Trials Group555 participantsStarted Jan 1997

Edmonton, Alberta, Canada • Penticton, British Columbia, Canada • Vancouver, British Columbia, Canada +35 more locations

Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients

Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer

Related Searches

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC

Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies

Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy

Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer

SRS Study in Patients With Non-Small Cell Lung Cancer

Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC

Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients

Validation of Multiparametric Models and Circulating and Imaging Biomarkers to Improve Lung Cancer EARLY Detection.

Study Using Combined Virtual 4-D Electromagnetic (EM) Tip-Tracked Devices & EBUS in Diagnosis of Lung Nodules

An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)

NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Circulating and Imaging Biomarkers to Improve Lung Cancer Management and Early Detection

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Clinical Trial of Sintilimab Combined With Gemcitabine/Carboplatin Regimen in the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma

Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC) GCC 0516